De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Moderna Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Moderna is gedaald met een gemiddeld jaarlijks percentage van -2.3%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 13.4%. De inkomsten zijn groeide met een gemiddeld percentage van 31.7% per jaar.

Belangrijke informatie

-2.3%

Groei van de winst

-2.0%

Groei van de winst per aandeel

Biotechs Groei van de industrie	14.8%
Inkomstengroei	31.7%
Rendement op eigen vermogen	-50.1%
Nettomarge	-116.2%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe Moderna geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

WBAG:MRNA Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven
30 Jun 24	5,050	-5,867	1,454
31 Mar 24	5,153	-5,968	1,518
31 Dec 23	6,848	-4,714	1,549
30 Sep 23	9,121	-3,466	1,454
30 Jun 23	10,654	1,207	1,290
31 Mar 23	15,059	4,784	1,169
31 Dec 22	19,263	8,362	1,132
30 Sep 22	21,390	11,765	958
30 Jun 22	22,995	14,055	848
31 Mar 22	22,600	14,638	758
31 Dec 21	18,471	12,202	567
30 Sep 21	11,831	7,061	445
30 Jun 21	7,019	3,495	325
31 Mar 21	2,732	598	241
31 Dec 20	803	-747	188
30 Sep 20	246	-597	135
30 Jun 20	106	-488	115
31 Mar 20	52	-505	106
31 Dec 19	60	-514	110
30 Sep 19	82	-535	122
30 Jun 19	106	-499	112
31 Mar 19	122	-459	105
31 Dec 18	135	-402	94
30 Sep 18	192	-299	72
30 Jun 18	192	-280	70
31 Mar 18	199	-266	65
31 Dec 17	206	-270	65
31 Dec 16	108	-230	57

Kwaliteitswinsten: MRNA is momenteel verliesgevend.

Groeiende winstmarge: MRNA is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: MRNA is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 2.3% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van MRNA over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: MRNA is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( -18.6% ).

Rendement op eigen vermogen

Hoge ROE: MRNA heeft een negatief Return on Equity ( -50.09% ), omdat het momenteel verliesgevend is.

Moderna Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2024 earnings released: US$3.33 loss per share (vs US$3.62 loss in 2Q 2023)

Moderna, Inc. to Report Q2, 2024 Results on Aug 01, 2024

First quarter 2024 earnings released: US$3.08 loss per share (vs US$0.20 profit in 1Q 2023)

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings released: US$12.34 loss per share (vs US$21.22 profit in FY 2022)

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Recent updates

Moderna, Inc. as Abbas Hussain to Board of Directors

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older

Moderna, Inc. Announces EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

Moderna, Inc. Receives Medicines and Healthcare Products Regulatory Agency Authorization for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

Taiwan Food & Drug Administration Approves Moderna, Inc.'s COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant JN.1

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

Moderna Receives European Commission Approval for RSV Vaccine Mresvia(R)

Gainey McKenna & Egleston Files Class Action Lawsuit Against Moderna Inc

Second quarter 2024 earnings released: US$3.33 loss per share (vs US$3.62 loss in 2Q 2023)

Moderna, Inc. Revises Earnings Guidance for the Year 2024

Moderna, Inc. Announces Board Changes

Moderna, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Moderna, Inc Announces EMA Committee for Medicinal Products for Human Use

Moderna, Inc. Announces Positive Phase 3 Efficacy Data for mRNA-1283

Moderna, Inc Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

Moderna Announces Update on Investigational Rsv Vaccine

First quarter 2024 earnings released: US$3.08 loss per share (vs US$0.20 profit in 1Q 2023)

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Insufficient new directors

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Full year 2023 earnings released: US$12.34 loss per share (vs US$21.22 profit in FY 2022)

Moderna, Inc., Annual General Meeting, May 06, 2024

CEO & Director recently sold €2.2m worth of stock

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

Moderna Announces Changes to Commercial Organization

Moderna Announces Changes to Commercial Organization

Moderna, Inc. Provides Sales Guidance for the Year 2023

Third quarter 2023 earnings released: US$9.53 loss per share (vs US$2.67 profit in 3Q 2022)

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine against Influenza and COVID-19

Investor sentiment deteriorates as stock falls 16%

Moderna, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Moderna, Inc. Announces Positive Phase 1/2 Data from mRNA-1083, the company's Combination Vaccine Against Influenza and COVID-19

Moderna, Inc. Announces Ema Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's Updated Covid-19 Vaccine in the European Union

Moderna Receives U.S. FDA Approval for Updated Covid-19 Vaccine

Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against Ba.2.86

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 19%

Moderna Clinical Trial Data Confirm its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

UMass Chan Medical School Announces Enrollment in Study to Explore Impact of Cytomegalovirus (CMV) Transmission in Early Education Settings

Moderna, Inc. Provides Sales Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$3.62 loss per share (vs US$5.55 profit in 2Q 2022)

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden